Results from a phase 2B randomized, double-blind, placebo-controlled trial suggest that semaglutide not only reduces inflammation and adiposity in people with HIV but may also provide a neurocognitive...
Excess visceral fat, rather than BMI alone, is a key driver of cardiovascular risk in people with HIV receiving antiretroviral therapy. The study authors presented their findings at the Conference on...
A new analysis found no difference in cardiovascular event rates between immediate and deferred antiretroviral therapy initiation among adults with HIV who had high CD4+ counts and low baseline...
Researchers tested the impact of four different remotely delivered interventions and observed promising effects on several key health outcomes in patients over the age of 50 living with HIV.
Researchers evaluated the safety and efficacy of dolutegravir plus lamivudine in treatment-naive individuals with HIV without baseline resistance testing.
A multi-center study finds kidney transplantation from HIV-positive donors to HIV-positive recipients is as safe and effective as using kidneys from HIV-negative donors, offering new insights into expanding...
A clinical trial suggests semaglutide significantly reduces abdominal fat in HIV-associated lipohypertrophy, but the potential for adverse events warrant further investigation.
In a study that assessed pericoronary adipose tissue (PCAT) density, researchers noted an association between higher PCAT density and greater coronary plaque burden and cardiovascular disease in people with...
A randomized clinical trial found that a nurse-led intervention strategy could improve systolic blood pressure and non-high-density lipoprotein cholesterol in patients with HIV, reducing their risk of...
